Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ikena Oncology, Inc. (IKNA : NSDQ)

• Company Description    Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $1.33 Daily Weekly Monthly 20 Day Moving Average: 58,415 shares Shares Outstanding: 48.26 (millions) Market Capitalization: $64.18 (millions) Beta: 0.50 52 Week High: $1.94 52 Week Low: $0.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.31% -3.23% 12 Week 25.47% 5.26% Year To Date -18.90% -24.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 645 SUMMER STREET SUITE 101 - BOSTON,MA 02210 USA ph: 857-273-8343 fax: - info@ikenaoncology.com http://www.ikenaoncology.com

• General Corporate Information    Officers Mark Manfredi - President; Chief Executive Officer and Director Jotin Marango - Chief Financial Officer; Chief Operating Officer Owen Hughes - Director David Bonita - Director Iain D. Dukes - Director Peer Information Ikena Oncology, Inc. (CORR.) Ikena Oncology, Inc. (RSPI) Ikena Oncology, Inc. (CGXP) Ikena Oncology, Inc. (BGEN) Ikena Oncology, Inc. (GTBP) Ikena Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45175G108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 48.26 Most Recent Split Date: (:1) Beta: 0.50 Market Capitalization: $64.18 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.58 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.54 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.71% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -30.59 12/31/24 - -32.10 ROA 06/30/25 - - 03/31/25 - -27.55 12/31/24 - -28.88 Current Ratio 06/30/25 - - 03/31/25 - 13.31 12/31/24 - 11.80 Quick Ratio 06/30/25 - - 03/31/25 - 13.31 12/31/24 - 11.80 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.45 12/31/24 - 2.61 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©